This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon (OGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $9.7, indicating a -3.39% shift from the previous trading day.
Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Organon (OGN) closed at $10.21, marking a +1.39% move from the previous day.
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
by Zacks Equity Research
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
OGN or MEDP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OGN vs. MEDP: Which Stock Is the Better Value Option?
Organon (OGN) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Organon (OGN) closed at $9.46 in the latest trading session, marking a -1.87% move from the prior day.
Why Organon (OGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon (OGN) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Organon (OGN) closed the most recent trading day at $10.02, moving +1.11% from the previous trading session.
Is Trending Stock Organon & Co. (OGN) a Buy Now?
by Zacks Equity Research
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon (OGN) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Organon (OGN) settling at $9.96, representing a -1.87% change from its previous close.
OGN vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
OGN vs. MEDP: Which Stock Is the Better Value Option?
Organon (OGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Organon (OGN) settling at $9.86, representing a -1.2% change from its previous close.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Organon (OGN) reached $9.95 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
All You Need to Know About Organon (OGN) Rating Upgrade to Buy
by Zacks Equity Research
Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OGN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OGN vs. DOCS: Which Stock Is the Better Value Option?
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Organon (OGN) closed at $10.19, indicating a +1.49% shift from the previous trading day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon (OGN) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 14.61% and 0.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?